- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Technical Perspectives: Antibody Drug Conjugates
December 7, 2011
Patricia Van Arnum
PTSM: Pharmaceutical Technology Sourcing and Management
PTSM: Pharmaceutical Technology Sourcing and Management-12-07-2011, Volume 7, Issue 12
A podcast moderated by Patricia Van Arnum, executive editor of Pharmaceutical Technology.
Antibody drug conjugates represent a niche area of drug development. Antibody drug conjugates combine a small-molecule, often a cytotoxic compound, to a monoclonal antibody. Grant E. Boldt, PhD, director of European business development for SAFC, discusses manufacturing considerations in producing antibody drug conjugates with Patricia Van Arnum, executive editor of Pharmaceutical Technology. Listen to the podcast.